{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:10:26Z","timestamp":1780571426192,"version":"3.54.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaacap.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jaac.2020.11.006","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T23:58:51Z","timestamp":1605571131000},"page":"816-817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-7383","authenticated-orcid":false,"given":"Benedetto","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2020.11.006_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase 2, superiority trial","volume":"60","author":"Sprengers","year":"2021","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.11.006_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2020.11.006_bib3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.neuron.2015.07.033","article-title":"Excitatory\/inhibitory balance and circuit homeostasis in autism spectrum disorders","volume":"87","author":"Nelson","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.jaac.2020.11.006_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaac.2020.11.006_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41398-018-0155-1","article-title":"Glutamate and GABA in autism spectrum disorder\u2014a translational magnetic resonance spectroscopy study in man and rodent models","volume":"8","author":"Horder","year":"2018","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jaac.2020.11.006_bib6","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jaac.2020.11.006_bib7","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/S0140-6736(16)31229-6","article-title":"Parent-mediated social communication therapy for young children with autism (PACT): long-term follow-up of a randomised controlled trial","volume":"388","author":"Pickles","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2020.11.006_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1362361314542955","article-title":"Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder","volume":"19","author":"Anagnostou","year":"2015","journal-title":"Autism"},{"key":"10.1016\/j.jaac.2020.11.006_bib9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder","volume":"44","author":"Pretzsch","year":"2019","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720320748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720320748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T18:57:37Z","timestamp":1721415457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856720320748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0890856720320748"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2020.11.006","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2020.07.888","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a92020 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}